- Home
- TPST vs PSTV Comparison
TPST vs PSTV Comparison
Compare TPST & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | PSTV |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 27.9M |
| IPO Year | 2012 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TPST | PSTV |
|---|---|---|
| Price | $2.03 | $6.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $11.00 | ★ $55.00 |
| AVG Volume (30 Days) | 278.7K | ★ 334.7K |
| Earning Date | 05-08-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | $295,000.00 | ★ $5,213,000.00 |
| Revenue This Year | N/A | $13.20 |
| Revenue Next Year | N/A | $261.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $0.13 |
| 52 Week High | $12.22 | $8.00 |
Technical Indicators
Market Signals| Indicator | TPST | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 62.94 |
| Support Level | $1.57 | $0.37 |
| Resistance Level | $2.48 | $8.00 |
| Average True Range (ATR) | 0.14 | 0.62 |
| MACD | 0.03 | -0.25 |
| Stochastic Oscillator | 67.59 | 26.80 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).